Brief: Cleveland Biolabs announces European Medicines Agency positive opinion regarding entolimod pediatric investigation plan
17/04/2017 12:32
April 17 (Reuters) - Cleveland Biolabs Inc CBLI.O
* Cleveland Biolabs announces European Medicines Agency
positive opinion regarding the entolimod pediatric investigation
plan
* Cleveland Biolabs - EMA accepted co's pediatric
investigation plan paving way for submission of MAA for
entolimod as medical radiation countermeasure
Source text for Eikon: ID:nMKW3jxl5a
Further company coverage: CBLI.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Statera Biopharma
See all news20/20 Biolabs jumps on Ebola, hantavirus testing plans
Tivic Health Systems rises after deal for late-stage immunotherapy drug
Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist
Brief: Statera Biopharma Inc Quarterly Loss Per Share $0.20
Brief: Statera Biopharma Inc - On October 12, 2022, Co Entered A Binding Memorandum Of Understanding (“MoU”) With Holobeam Technologies, Inc